About Us

 

MBio Diagnostics will be the platform of choice for on-the-spot testing across industries and applications. When we think of on-the-spot testing, we often think of home pregnancy tests—quick and convenient, but can leave you guessing when the results are faint. That uncertainty defines the limitations of today’s technology, based on paper strips with minimal controls and an inherent ambiguity that is not fixed even with an “electronic eye” readout. The desired solution is a system that provides precise quantitative readout, while preserving the simplicity and speed of the “home pregnancy”-type test.

The need for rapid, on-the-spot testing is large, totaling over $8B across medical, veterinary, food, and environmental testing. More than one billion units of the crude paper tests are manufactured each year. Recognizing the limitations of traditional visual interpretation, a half dozen major manufacturers have implemented electronic eye readout. This is an incremental but incomplete solution, and both end-users and the manufacturers continue searching for a true next generation approach.

There have been dozens of attempts to deliver high quality rapid testing beyond the traditional paper test. This technology is called “lab on a chip”, often integrating electronic chips and nanometer-sized features into complex microfluidic devices that try to replicate the procedures of a laboratory. The approach is costly, and subject to field-failures such as clogging of the nanometer-sized features. MBio has approached the problem from the ground up, tapping into our team’s deep understanding of measurement science to keep the devices simple and sensitive. MBio employs a unique waveguide approach—our LightDeck® technology—that not only simplifies the test processes, but allows simplified manufacturing steps. The uniqueness is embodied in over two dozen issued patents and patent applications in process. MBio is enjoying rapid acceptance of our platform for bringing new and existing tests to the point-of-use.

Click here for the MBio Fact Sheet

 

In addition to MBio’s experienced management team, the company’s technical team consists of a select, accomplished, and integrated group of instrumentation engineers, biological assay scientists, and disposable cartridge developers. MBio’s state-of-the-art facility in Boulder includes fully equipped biosafety laboratories for biological assay development, method development and validation. The facility also includes a 3750-sq. ft. cleanroom for pilot-scale cartridge production and cartridge manufacturing process development.

Leadership

 

Christopher J. Myatt, Ph.D.
Chief Executive Officer

Dr. Myatt is the founder and CEO of MBio Diagnostics, Inc. He is an entrepreneur with a proven track record for building technology companies, securing patents and licensing technology, raising funding, establishing commercial operations, and leading through growth. Prior to MBio Diagnostics, Chris successfully founded and led Precision Photonics Corporation, a successful laser and optical technology supplier that is now a division of IDEX. Trained as a physicist and measurement scientist, Chris invented and developed multiple technologies that formed the basis of his companies. He earned a B.S. in Physics and a B.A. in Mathematics at Southern Methodist University. Chris also earned a Ph.D. in Atomic Physics at the University of Colorado. He studied Bose-Einstein Condensation (BEC) under Carl Wieman (Nobel Prize, 2001), helping to create the first BEC condensate in the Wieman lab. He also studied quantum information under David Wineland (Nobel Prize, 2012) as a National Research Council (NRC) Postdoctoral Fellow at the National Institute of Standards and Technology (NIST) in Boulder.

 

Michael J. Lochhead, Ph.D.
Executive Vice President and Chief Technology Officer

Dr. Lochhead is a co-founder of MBio and leads technical development, collaborator activities, and intellectual property strategy. He serves as Program Manager on MBio’s commercial partnerships and is Principal Investigator on multiple major contracts with agencies including NIH, NSF and DARPA. Mike leads MBio’s talented team of instrumentation engineers and assay development scientists, and he has overall responsibility for operational scale-up of MBio’s disposable cartridge production line. Previously, Mike developed and commercialized microarray surface chemistry products at Accelr8 Technology Corporation (now Accelerate Diagnostics, Inc) where he was also part of the engineering team developing the company’s bacterial identification technology. He earned his Ph.D. in Chemical Engineering from the University of Wisconsin, Madison and completed post-doctoral training in Bioengineering at the University of Washington, Seattle. He holds B.S. and B.A. degrees from the University of Notre Dame, and is co-inventor on multiple pending and issued U.S. and international patents.

Board of Directors

 

Christopher J. Myatt, Ph.D.
Chief Executive Officer and Director

Dr. Myatt is the founder and CEO of MBio Diagnostics, Inc. He is an entrepreneur with a proven track record for building technology companies, securing patents and licensing technology, raising funding, establishing commercial operations, and leading through growth. Prior to MBio Diagnostics, Chris successfully founded and led Precision Photonics Corporation, a successful laser and optical technology supplier that is now a division of IDEX. Trained as a physicist and measurement scientist, Chris invented and developed multiple technologies that formed the basis of his companies. He earned a B.S. in Physics and a B.A. in Mathematics at Southern Methodist University. Chris also earned a Ph.D. in Atomic Physics at the University of Colorado. He studied Bose-Einstein Condensation (BEC) under Carl Wieman (Nobel Prize, 2001), helping to create the first BEC condensate in the Wieman lab. He also studied quantum information under David Wineland (Nobel Prize, 2012) as a National Research Council (NRC) Postdoctoral Fellow at the National Institute of Standards and Technology (NIST) in Boulder.

 

Milton Chang, Ph.D.
Director

Milton Chang, Ph.D., is an angel investor mentoring and advising entrepreneurs (www.incubic.com). He is the author of Toward Entrepreneurship (www.miltonchang.com). Dr. Chang has served on many boards, and was president/CEO of Newport and New Focus, taking both companies public. He has also successfully incubated more than a dozen startup companies. Dr. Chang earned a B.S. in Electrical Engineering with highest honors from the University of Illinois and an M.S. and Ph.D. from the California Institute of Technology. He was awarded Distinguished Alumni by both universities and is a Trustee of Caltech. Dr. Chang has served on the Visiting Committee of NIST and also on an SEC advisor board.

 

Robert J. Silverman
Director

Robert J. Silverman is a director and strategic advisor to the company. He served as the CEO of mtm laboratories AG, an in-vitro diagnostics company that developed and commercialized a portfolio of products for the early detection and diagnosis of cervical cancer. Bob was instrumental in raising capital and building mtm laboratories into a global, fully-integrated commercial business. He led the company to a $240 Million exit to Roche Diagnostics. Prior to leading mtm laboratories, he held senior executive positions at Viacell, Cytyc Corporation, Pasteur Merieux and Abbott Laboratories Pharmaceuticals. He earned his Master’s Degree in Marketing and Finance from the Kellogg Graduate School of Management at Northwestern University. Bob received his B.S. in Pharmacy from the University of Michigan. He currently works with several companies in a Board and Advisory capacity.